EUVIMEDEUVIMED entdecken
Crossref

Revisiting Amantadine as A Treatment for Drug-Induced Movement Disorders

Stanley N. Caroff, Rakesh Jain, James F. Morley

Annals of Clinical Psychiatry · 2020-08 · 32 (3) · 198-208

DOI: 10.1177/104012372003200309 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical Psychiatry, 2020-08. Verfasst von Stanley N. Caroff und 2 weiteren Autor:innen. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 135 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Amantadine, an aliphatic primary amine with complex actions on neurotransmitter systems in the basal ganglia, is approved for treating Parkinson's disease and drug-induced movement disorders (DIMDs). These disorders have a significant impact on clinical outcomes and quality of life in patients receiving antipsychotic treatment.

Methods

We searched PubMed up to June 1, 2019 to identify relevant studies. The following search terms were used: “amantadine” AND “dys-tonia,” “parkinsonism, ” “akathisia,” “tardive dyskinesia,” “catatonia,” “neuroleptic malignant syndrome.” Reference lists were reviewed for additional material.

Results

Evidence from multiple, small, controlled trials supports the efficacy of amantadine as a treatment for drug-induced parkinsonism. Studies show amantadine has a more favorable tolerability profile than anticholin-ergic medications in these patients. Clinical evidence from observational studies and case reports suggests that further trials might be warranted to support use of amantadine in select patients for preventing dystonic reactions and as a second-line agent for treating catatonia, neuroleptic malignant syndrome, and tardive dyskinesia. Evidence is lacking on the use of amantadine specifically for akathisia relative to other treatments.

Conclusions

Amantadine is an evidence-based pharmacologic strategy for treating drug-induced parkinsonism and might be an alternative treatment for other DIMDs in select patients. Additional randomized controlled trials are needed.

Zitieren

APA

Caroff, S. N., Jain, R., & Morley, J. F. (2020). Revisiting Amantadine as A Treatment for Drug-Induced Movement Disorders. Annals of Clinical Psychiatry, 32(3), 198-208. https://doi.org/10.1177/104012372003200309

Vancouver

Caroff SN, Jain R, Morley JF. Revisiting Amantadine as A Treatment for Drug-Induced Movement Disorders. Annals of Clinical Psychiatry. 2020;32(3):198-208. doi:10.1177/104012372003200309

BibTeX
@article{Caroff2020,
  author = {Caroff, Stanley N. and Jain, Rakesh and Morley, James F.},
  title = {Revisiting Amantadine as A Treatment for Drug-Induced Movement Disorders},
  journal = {Annals of Clinical Psychiatry},
  year = {2020},
  volume = {32},
  number = {3},
  pages = {198--208},
  doi = {10.1177/104012372003200309}
}
Kostenlos starten →